Related Experiment Video
Updated: Mar 24, 2026
04:34
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
1.7K
Risperidone-Induced Nocturnal Enuresis Successfully Treated With Reboxetine
Joseph Mergui1, Sol Jaworowski
1Department of Consultation and Liaison Psychiatry, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Clinical Neuropharmacology
|March 19, 2016
Summary
Antipsychotic medications can cause urinary incontinence or nocturnal enuresis (NE). This report details a successful reboxetine treatment for NE induced by risperidone, suggesting a new therapeutic option.
Area of Science:
- Pharmacology
- Neuroscience
- Urology
Background:
- Antipsychotic medications are frequently associated with adverse effects, including urinary incontinence and nocturnal enuresis (NE), yet research and treatment options remain limited.
- Previous treatments for antipsychotic-induced urinary incontinence, particularly with clozapine, have involved various pharmacological agents like ephedrine, oxybutynin, desmopressin, trihexyphenidyl, and amitriptyline.
Observation:
- This case report describes a patient experiencing nocturnal enuresis (NE) secondary to risperidone use.
- The patient's NE was effectively managed with reboxetine, an norepinephrine reuptake inhibitor.
Findings:
- This is the first reported instance of atypical antipsychotic-induced NE successfully treated with reboxetine.
- Reboxetine demonstrates potential efficacy in treating risperidone-induced nocturnal enuresis.
Implications:
- Reboxetine may represent a novel and effective treatment strategy for nocturnal enuresis caused by risperidone.
- Further research is warranted to validate these findings and explore reboxetine's utility for NE induced by other antipsychotic medications.
Related Concept Videos
01:15REM Sleep Behavior Disorder
2.4K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
2.4K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
805
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
805
01:23Antidepressant Drugs: MAOIs and Other Agents
1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
01:27Restless Leg Syndrome and Night Terrors
753
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
753
01:20Antiepileptic Drugs: Potassium Channel Activators
916
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
916
01:19Management of Insomnia
767
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
767